(Q37216921)

19 August 2017

1 reference

title

Better pharmacotherapy for schizophrenia: what does the future hold? (English)

1 reference

19 August 2017

0 references

0 references

Michael A Webber

1

1 reference

19 August 2017

Stephen R Marder

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

Current Psychiatry Reports

19 August 2017

published in

1 reference

19 August 2017

volume

10

1 reference

19 August 2017

issue

4

1 reference

19 August 2017

page(s)

352-358

1 reference

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

19 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11920-008-0056-8

Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11920-008-0056-8

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11920-008-0056-8

Identification of separable cognitive factors in schizophrenia

21 January 2018

1 reference

12 December 2020

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

12 December 2020

Persistent negative symptoms in schizophrenia: an overview

1 reference

12 December 2020

Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia

1 reference

12 December 2020

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

1 reference

12 December 2020

Towards a muscarinic hypothesis of schizophrenia.

1 reference

12 December 2020

Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications

1 reference

12 December 2020

Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study

1 reference

12 December 2020

Negative symptoms of schizophrenia: a problem that will not go away

1 reference

12 December 2020

Molecular targets for treating cognitive dysfunction in schizophrenia.

1 reference

12 December 2020

Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial

1 reference

12 December 2020

Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations

1 reference

12 December 2020

Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation

1 reference

12 December 2020

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

1 reference

12 December 2020

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

1 reference

12 December 2020

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

1 reference

12 December 2020

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

1 reference

12 December 2020

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

1 reference

12 December 2020

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

1 reference

12 December 2020

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

1 reference

12 December 2020

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

12 December 2020

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

1 reference

12 December 2020

Galantamine for the treatment of cognitive impairments in people with schizophrenia

1 reference

12 December 2020

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

1 reference

12 December 2020

Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Pharmacology of N-desmethylclozapine

1 reference

12 December 2020

Heterogeneity in recovery of psychosocial functioning during psychiatric rehabilitation: an exploratory study using latent growth mixture modeling

1 reference

12 December 2020

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

1 reference

12 December 2020

Remission and recovery in schizophrenia: practitioner and patient perspectives

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Cortical inhibitory neurons and schizophrenia

1 reference

12 December 2020

Guanfacine treatment of cognitive impairment in schizophrenia

1 reference

12 December 2020

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

1 reference

12 December 2020

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

12 December 2020

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

1 reference

12 December 2020

Stimulating the development of drug treatments to improve cognition in schizophrenia

1 reference

12 December 2020

Clinical constructs and therapeutic discovery

1 reference

12 December 2020

Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings.

1 reference

12 December 2020

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

12 December 2020

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

12 December 2020

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site

1 reference

12 December 2020

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

1 reference

12 December 2020

How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia

1 reference

12 December 2020

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

12 December 2020

10.1007/S11920-008-0056-8

Identifiers

DOI

1 reference

19 August 2017

1 reference